Tim Kutzkey

Dr. Kutzkey joined The Column Group in 2007 and has since contributed to the conception, formation, and management of many of the firm’s portfolio companies. He currently serves as a Board Director of Peloton Therapeutics, a company he launched in 2010, as the interim President and CEO. In addition to Peloton, Dr. Kutzkey serves as a member of the Board of Directors of both Nurix and Carmot Therapeutics and is a Board Observer at Igenica. Dr. Kutzkey was formerly a scientist at KAI Pharmaceuticals, focused on the discovery and development of selective protein kinase C inhibitors. Prior to KAI, he worked at UC Berkeley as a graduate student and postdoctoral scholar in the lab of Dr. Robert Tjian, completing his Ph.D. in 2005. Dr. Kutzkey was previously educated at Stanford University. Board of Directors: Peloton Therapeutics, Nurix, Carmot Therapeutics